Synthetic biology

Elicit Plant Announces the Appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)

Retrieved on: 
Thursday, March 7, 2024

Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).

Key Points: 
  • Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).
  • Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
  • "In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform.
  • We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Thursday, March 7, 2024

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

Novel Bio announces collaborative partnership with Culture Biosciences to scale-up NBx Platform™ for plasmid DNA production

Retrieved on: 
Tuesday, March 5, 2024

Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA for use in genetic medicines, announced today that they have formed a partnership with Culture Biosciences to accelerate the development of scalable fermentation processes for their proprietary NBx Platform™ for plasmid DNA production.

Key Points: 
  • Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA for use in genetic medicines, announced today that they have formed a partnership with Culture Biosciences to accelerate the development of scalable fermentation processes for their proprietary NBx Platform™ for plasmid DNA production.
  • View the full release here: https://www.businesswire.com/news/home/20240305254120/en/
    Since the 1970s, plasmid DNA has been produced using the simple bacterium E. coli.
  • For the past 2 years Novel Bio has been developing a new microbe to solve key manufacturing challenges.
  • “Instead, we decided to partner with Culture Biosciences to access their amazing team and their custom-built, cloud-connected bioreactors.

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

Retrieved on: 
Wednesday, February 28, 2024

bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
  • The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
  • As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem.
  • bit.bio’s ioCells products are precision reprogrammed from iPSCs using bit.bio’s opti-ox TM technology.

ORI Capital Raises $260 Million for Second Life Sciences Fund

Retrieved on: 
Thursday, February 22, 2024

ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.

Key Points: 
  • ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.
  • Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies.
  • ORI Capital is a pioneer in adopting a quantamental strategy in biotech venture investment combing data analysis with fundamental research.
  • ORI Healthcare Fund II will actively deploy capital in these new approaches to support truly innovative companies that can bring hope to patients in need globally.

Dr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy

Retrieved on: 
Friday, March 8, 2024

PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).

Key Points: 
  • PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).
  • "We are thrilled to have Dr. David Liu on board to guide our initiatives," said Sherry Shao, Rotating Chief Executive Officer of GenScript.
  • "Dr. Liu's extensive knowledge and innovation will be instrumental to GenScript as we strive to enhance our platform with the aim of accelerating transformative breakthroughs to patients."
  • With Dr. Liu's addition, GenScript's SAB now encompasses leading experts across the full spectrum of genome editing and cell and gene therapy.

Register Now for B&C's "FIFRA Hot Topics" Webinar on March 12, 2024, 11:00 a.m. - 12:00 p.m. (EDT)

Retrieved on: 
Wednesday, February 14, 2024

WASHINGTON, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Register now to join Bergeson & Campbell, P.C. (B&C®) for "FIFRA Hot Topics," a complimentary webinar covering key priorities for the U.S. Environmental Protection Agency (EPA) Office of Pesticide Programs (OPP) and what companies should know to avoid market entry delays and other commercial disruptions.

Key Points: 
  • WASHINGTON, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Register now to join Bergeson & Campbell, P.C.
  • In 2024, OPP's core focus can be expected to be on making further progress on integrating ESA with registration activities and PRIA 5 implementation.
  • James V. Aidala , Senior Government Affairs Consultant, B&C, is a critical ally for any client addressing chemical policy, legislative, and related issues.
  • He has been intimately involved with FIFRA and Toxic Substances Control Act (TSCA) legislative reauthorization and key regulatory matters for over four decades.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Retrieved on: 
Wednesday, February 7, 2024

SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencing solutions, and seqWell, a global provider of genomic library preparation workflow solutions, today announced a partnership aimed at expanding the range of library preparation product offerings available to Complete Genomics customers. The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.

Key Points: 
  • The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.
  • "Our partnership with seqWell enables us to offer a broader range of tools to support a broader range of customer needs."
  • Leveraging the power of the Complete Genomics DNBSEQ-G400RS * and seqWell purePlex ™ DNA Library Prep Kit , this partnership will allow customers to the ability to run cost-effective and scalable workflows pairing seqWell library prep kits with Complete Genomics' portfolio of DNBSEQ technologies.
  • The latest outcome of this partnership enables customers to pair seqWell's ExpressPlex ™ library prep kits with Complete Genomics' portfolio of DNBSEQ technologies, including the DNBSEQ-G-99 RS* and DNBSEQ-T7 RS* sequencers.

Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors

Retrieved on: 
Tuesday, February 6, 2024

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.
  • "The field of animal health is hungry for innovative solutions to address our pets' health concerns,” said Aaron Schacht.
  • Mr. Schacht led several strategic acquisitions, including Bayer Animal Health, Aratana Therapeutics, and Kindred Biosciences.
  • Additionally, he integrated R&D capabilities and pipelines from Novartis Animal Health, Boehringer Ingelheim pet vaccines, Bayer Animal Health, Aratana, Prevtec, and Kindred.